Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1

Journal of Cellular Physiology

Volumn 227, Issue 5, 2012, Pages 2184-2195

  Rajendran, Peramaiyan ^a   Li, Feng ^a   Shanmugam, Muthu K ^a   Vali, Shireen ^b,c   Abbasi, Taher ^b,c   Kapoor, Shweta ^b,c   Ahn, Kwang Seok ^d   Kumar, Alan Prem ^a,e   Sethi, Gautam ^a,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CELLWORKS GROUP INC   (United States)

^c Cellworks Research India Pvt Ltd   (India)

^d Kyung Hee University   (South Korea)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELL PROTEIN; CYCLIN D1; DOXORUBICIN; HONOKIOL; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; STAT3 PROTEIN; SURCIVIN; UNCLASSIFIED DRUG; VANADIC ACID; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEOMICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIPHENYL COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; G1 PHASE; GENES, REPORTER; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; LIGNANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84862907992     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22954     Document Type: Article

References (66)

1. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H. 2006. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: Modern target but ancient solution. Ann N Y Acad Sci 1091: 151-169.
2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. 2009. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann N Y Acad Sci 1171: 59-76.
3. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. 2006. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 4: 621-633.
4. Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P. 2011. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10: 21-27.
5. Avila MA, Berasain C, Sangro B, Prieto J. 2006. New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884.
6. Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19: 2474-2488.
7. Bromberg J, Darnell JE, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
8. Bromberg J, Wang TC. 2009. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80.
9. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. 2006. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128.
10. Campbell GS, Yu CL, Jove R, Carter-Su C. 1997. Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 272: 2591-2594.
11. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. 1999. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 274: 23013-23019.
12. Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. 2004. Honokiol: A potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol 10: 3459-3463.
13. Chilampalli S, Zhang X, Fahmy H, Kaushik RS, Zeman D, Hildreth MB, Dwivedi C. 2010. Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res 30: 777-783.
14. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. 2010. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9: 963-975.
15. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. 2009. Honokiol-mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 32: 585-592.
16. Darnell JE, Jr. 1997. STATs and gene regulation. Science 277: 1630-1635.
17. Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, Yan S, Jiang G, Zhou L, Zheng S. 2008. Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int 28: 1458-1464.
18. Digicaylioglu M, Lipton SA. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647.
19. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP, Jr. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362.
20. Fried LE, Arbiser JL. 2009. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 11: 1139-1148.
21. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Masuya M, Takei Y. 2007. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 363: 738-744.
22. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
23. Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, Brown HA, Bar-Sagi D, Foster DA, Arbiser JL. 2008. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res 14: 4267-4274.
24. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. 2006. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19.
25. Grivennikov SI, Karin M. 2010. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11-19.
26. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. 2008. Honokiol, a constituent of oriental medicinal herb Magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 14: 1248-1257.
27. Han Y, Amin H, Franko B, Frantz C, Shi X, Lai R. 2006. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood 108: 2796-2803.
28. He G, Karin M. 2011. NF-kappaB and STAT3-Key players in liver inflammation and cancer. Cell Res 21: 159-168.
29. Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J, Chen X, Wang X, Yuan Y, Tang M, Wen J, Wei Y. 2008. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res 22: 1125-1132.
30. Ihle JN. 1996. STATs: Signal transducers and activators of transcription. Cell 84: 331-334.
31. Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. 2010. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 136: 267-274.
32. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Chng WJ, Sethi G. 2011. Celastrol inhibits proliferation and induces chemosensitization through downregulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol
33. Kerr SH, Kerr DJ. 2009. Novel treatments for hepatocellular cancer. Cancer Lett 286: 114-120.
34. Lee J, Jung E, Park J, Jung K, Lee S, Hong S, Park E, Kim J, Park S, Park D. 2005. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 71: 338-343.
35. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. 2009. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15: 283-293.
36. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. 2010. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2571-2579.
37. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG, Zhang H. 2006. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12: 7140-7148.
38. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. 2010. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 292: 197-207.
39. Lin H, van den Esschert J, Liu C, van Gulik TM. 2011. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol 26: 28-35.
40. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. 2003. The anti-inflammatory effect of honokiol on neutrophils: Mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 475: 19-27.
41. Liu SH, Shen CC, Yi YC, Tsai JJ, Wang CC, Chueh JT, Lin KL, Lee TC, Pan HC, Sheu ML. 2010. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br J Pharmacol 160: 1963-1972.
42. Macha MA, Matta A, Chauhan SS, Siu KW, Ralhan R. 2011. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-kappaB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 32: 368-380.
43. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. 1991. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701-713.
44. Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. 2008. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 147: 23-33.
45. Newman DJ. 2008. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J Med Chem 51: 2589-2599.
46. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
47. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
48. Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, Khuri FR, Sun SY. 2008. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 7: 2212-2223.
49. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. 2011. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17: 1425-1439.
50. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. 2008. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 49: 977-984.
51. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, Reddanna P. 2010. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 65: 903-911.
52. Schreiner SJ, Schiavone AP, Smithgall TE. 2002. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277: 45680-45687.
53. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M. 2010. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 126: 2049-2066.
54. Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. 2007. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109: 1279-1289.
55. Son HJ, Lee HJ, Yun-Choi HS, Ryu JH. 2000. Inhibitors of nitric oxide synthesis and TNF-alpha expression from Magnolia obovata in activated macrophages. Planta Med 66: 469-471.
56. Sun X, Zhang J, Wang L, Tian Z. 2008. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213.
57. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. 2010. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334: 285-293.
58. Vaid M, Sharma SD, Katiyar SK. 2010. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: Development of topical formulation. Carcinogenesis 31: 2004-2011.
59. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. 2007. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 30: 1529-1537.
60. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW. 2003. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 90: 1026-1037.
61. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R. 2010. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 9: 953-962.
62. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R. 1995. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
63. Yu Z, Zhang W, Kone BC. 2002. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367: 97-105.
64. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9: 798-809.
65. Yue P, Turkson J. 2009. Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs 18: 45-56.
66. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. 2002. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466-474.